KROS — Keros Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1664710 ·
Last close
$11.62
Market Cap
$230.39M
52W High
$22.55
52W Low
$9.69
ADV30
192,537
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -30,937,000 | -28,710,000 | 287,600,000 | 257,606,000 | 25,280,000 |
| Mar 2026 | 367,000 | — | -25,877,000 | -23,708,000 | 312,293,000 | 281,497,000 | 26,663,000 |
| Dec 2025 | 385,000 | — | -29,270,000 | -23,461,000 | 338,021,000 | 287,415,000 | 34,889,000 |
| Sep 2025 | 14,262,000 | — | -15,384,000 | -7,280,000 | 742,783,000 | 693,472,000 | 39,203,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,993,000
Investing CF
$-494,000
Financing CF
$-384,122,000
CapEx
$-494,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.70
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-534,183,000
Inventory
—
Receivables
$2,757,000
ST Investments
—
EBIT TTM
$-101,468,000
Pretax Income TTM
$-86,097,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,014,000
EBITDA
$-96,868,000
Free Cash Flow
$-27,174,500
Enterprise Value
$-22,196,756
Total Cash
$257,606,000
Total Debt
$15,724,000
Shares Out
19,827,188
Trailing EPS
$-3.22
Book Value
$13.23
ROE
-17.2%
ROA
-11.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 244,061,000 | 67,569,000 | 87,014,000 | 338,021,000 | 34,889,000 | 303,132,000 | 107,505,000 |
| Dec 2024 | 3,550,000 | -209,595,000 | -187,353,000 | 615,886,000 | 44,333,000 | 571,553,000 | -160,869,000 |
| Dec 2023 | 151,000 | -167,541,000 | -152,992,000 | 370,025,000 | 37,812,000 | 332,213,000 | -124,508,000 |
| Dec 2022 | 0 | -107,709,000 | -104,679,000 | 306,781,000 | 29,358,000 | 277,423,000 | -70,062,000 |
TTM Snapshot
Revenues TTM
$211,642,000
NetIncome TTM
$32,546,000
OpCashFlow TTM
$0
Assets (Latest)
$338,021,000
Forward EPS
$-6.62
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $11.24 · call volume: 6 · put volume: 10Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CUE | Cue Biopharma, Inc. | $228.18M | $31.41 | — |
| PRQR | ProQR Therapeutics N.V. | $232.85M | $1.65 | — |
| NATR | NATURES SUNSHINE PRODUCTS INC | $227.33M | $12.92 | — |
| SION | Sionna Therapeutics, Inc. | $236.14M | $5.23 | — |
| RNAC | Cartesian Therapeutics, Inc. | $224.19M | $7.41 | — |
News headlines (Yahoo Finance, 1h cache)
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
2026-09-28 12:00 · Yahoo
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
2026-09-02 15:30 · Yahoo
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?
2026-08-14 23:37 · Yahoo
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
2026-07-30 20:01 · Yahoo
Keros Therapeutics Appoints Anne Prener to its Board of Directors
2026-06-25 20:01 · Yahoo
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-01 20:01 · Yahoo
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20
2026-05-17 13:36 · Yahoo
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
2026-04-03 15:30 · Yahoo
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
2026-09-08 20:01 · Yahoo
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
2026-08-24 16:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.